iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer
A major challenge in the management of patients with prostate cancer is identifying those individuals at risk of developing metastatic disease, as in most cases the disease will remain indolent. We analyzed pooled serum samples from 4 groups of patients (n = 5 samples/group), collected prospectively...
Gespeichert in:
| Veröffentlicht in: | PloS one 2012-02, Vol.7 (2), p.e30885-e30885 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e30885 |
|---|---|
| container_issue | 2 |
| container_start_page | e30885 |
| container_title | PloS one |
| container_volume | 7 |
| creator | Rehman, Ishtiaq Evans, Caroline A Glen, Adam Cross, Simon S Eaton, Colby L Down, Jenny Pesce, Giancarlo Phillips, Joshua T Yen, Ow Saw Thalmann, George N Wright, Phillip C Hamdy, Freddie C |
| description | A major challenge in the management of patients with prostate cancer is identifying those individuals at risk of developing metastatic disease, as in most cases the disease will remain indolent. We analyzed pooled serum samples from 4 groups of patients (n = 5 samples/group), collected prospectively and actively monitored for a minimum of 5 yrs. Patients groups were (i) histological diagnosis of benign prostatic hyperplasia with no evidence of cancer 'BPH', (ii) localised cancer with no evidence of progression, 'non-progressing' (iii) localised cancer with evidence of biochemical progression, 'progressing', and (iv) bone metastasis at presentation 'metastatic'. Pooled samples were immuno-depleted of the 14 most highly abundant proteins and analysed using a 4-plex iTRAQ approach. Overall 122 proteins were identified and relatively quantified. Comparisons of progressing versus non-progressing groups identified the significant differential expression of 25 proteins (p |
| doi_str_mv | 10.1371/journal.pone.0030885 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1332949097</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A477083364</galeid><doaj_id>oai_doaj_org_article_7a4c7d04ad2d482c8657cbddab3a930d</doaj_id><sourcerecordid>A477083364</sourcerecordid><originalsourceid>FETCH-LOGICAL-c691t-d26d1d788d94b23e217ef951ff89fc04105801111add5e8ca3acba5dd3a4acd73</originalsourceid><addsrcrecordid>eNqNk9tu1DAQhiMEoqXwBggiIYG42MWHHOwbpFXFYaVKFaVwa008zq6XJF7shMPb47BptUG9ILlINPP9vzOTmSR5SsmS8pK-2bnBd9As964zS0I4ESK_l5xSydmiYITfP3o_SR6FsCMk56IoHiYnjPE855ydJt5eX60-pRZN19vaauit61JXpxo6tAi9SYPxQ5tW1rXgvxkfUgjBaRtTmP60_TZtTQ-hj0qd7r3beBPCZLIdWujG4Jg2o6c2_nHyoIYmmCfT8yz58v7d9fnHxcXlh_X56mKhC0n7BbICKZZCoMwqxg2jpallTutayFqTjJJcEBovQMyN0MBBV5AjcshAY8nPkucH333jgpraFRSNdctMEjkS6wOBDnZq722s8LdyYNXfgPMbBT6W1RhVQqZLJBkgw0wwLYq81BUiVBwkJxi93k6nDVVrUMd-emhmpvNMZ7dq434ozgRhOY0GryYD774PJvSqtUGbpoHOuCEoyTiVRDAeyRf_kHcXN1EbiN9vu9rFY_XoqVZZWRLBeZFFankHFW80rdVxtGob4zPB65kgMr351W9gCEGtP1_9P3v5dc6-PGK3Bpp-G1wzjPMY5mB2AHUcq-BNfdtjStS4GTfdUONmqGkzouzZ8f-5Fd2sAv8DNaQLhw</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1332949097</pqid></control><display><type>article</type><title>iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Rehman, Ishtiaq ; Evans, Caroline A ; Glen, Adam ; Cross, Simon S ; Eaton, Colby L ; Down, Jenny ; Pesce, Giancarlo ; Phillips, Joshua T ; Yen, Ow Saw ; Thalmann, George N ; Wright, Phillip C ; Hamdy, Freddie C</creator><contributor>Chai, Karl X.</contributor><creatorcontrib>Rehman, Ishtiaq ; Evans, Caroline A ; Glen, Adam ; Cross, Simon S ; Eaton, Colby L ; Down, Jenny ; Pesce, Giancarlo ; Phillips, Joshua T ; Yen, Ow Saw ; Thalmann, George N ; Wright, Phillip C ; Hamdy, Freddie C ; Chai, Karl X.</creatorcontrib><description>A major challenge in the management of patients with prostate cancer is identifying those individuals at risk of developing metastatic disease, as in most cases the disease will remain indolent. We analyzed pooled serum samples from 4 groups of patients (n = 5 samples/group), collected prospectively and actively monitored for a minimum of 5 yrs. Patients groups were (i) histological diagnosis of benign prostatic hyperplasia with no evidence of cancer 'BPH', (ii) localised cancer with no evidence of progression, 'non-progressing' (iii) localised cancer with evidence of biochemical progression, 'progressing', and (iv) bone metastasis at presentation 'metastatic'. Pooled samples were immuno-depleted of the 14 most highly abundant proteins and analysed using a 4-plex iTRAQ approach. Overall 122 proteins were identified and relatively quantified. Comparisons of progressing versus non-progressing groups identified the significant differential expression of 25 proteins (p<0.001). Comparisons of metastatic versus progressing groups identified the significant differential expression of 23 proteins. Mapping the differentially expressed proteins onto the prostate cancer progression pathway revealed the dysregulated expression of individual proteins, pairs of proteins and 'panels' of proteins to be associated with particular stages of disease development and progression. The median immunostaining intensity of eukaryotic translation elongation factor 1 alpha 1 (eEF1A1), one of the candidates identified, was significantly higher in osteoblasts in close proximity to metastatic tumour cells compared with osteoblasts in control bone (p = 0.0353, Mann Whitney U). Our proteomic approach has identified leads for potentially useful serum biomarkers associated with the metastatic progression of prostate cancer. The panels identified, including eEF1A1 warrant further investigation and validation.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0030885</identifier><identifier>PMID: 22355332</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Aged ; Androgens ; Antigens ; Biocompatibility ; Bioengineering ; Biological markers ; Biology ; Biomarkers ; Biomarkers, Tumor - genetics ; Biomarkers, Tumor - metabolism ; Biomedical materials ; Blotting, Western ; Bone cancer ; Bone Neoplasms - genetics ; Bone Neoplasms - metabolism ; Bone Neoplasms - secondary ; Bones ; Cancer ; Cancer metastasis ; Cloning ; Cytokines ; Developmental stages ; Diagnosis ; Disease ; Disease Progression ; Elongation ; Health risks ; Humans ; Hyperplasia ; Identification ; Immunoenzyme Techniques ; Male ; Mass spectrometry ; Medical diagnosis ; Medical prognosis ; Medical schools ; Medicine ; Metabolism ; Metastases ; Metastasis ; Neoplasm Grading ; Osteoblasts ; Osteosarcoma - genetics ; Osteosarcoma - metabolism ; Osteosarcoma - secondary ; Panels ; Patients ; Peptide Elongation Factor 1 - genetics ; Peptide Elongation Factor 1 - metabolism ; Peptide mapping ; Prospective Studies ; Prostate cancer ; Prostate-Specific Antigen - blood ; Prostatic Hyperplasia - genetics ; Prostatic Hyperplasia - metabolism ; Prostatic Hyperplasia - pathology ; Prostatic Neoplasms - genetics ; Prostatic Neoplasms - metabolism ; Prostatic Neoplasms - pathology ; Proteins ; Proteomics ; Real-Time Polymerase Chain Reaction ; RNA, Messenger - genetics ; Scientific imaging ; Tandem Mass Spectrometry ; Translation elongation ; Tumor Cells, Cultured ; Tumors ; Urology</subject><ispartof>PloS one, 2012-02, Vol.7 (2), p.e30885-e30885</ispartof><rights>COPYRIGHT 2012 Public Library of Science</rights><rights>2012 Rehman et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Rehman et al. 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c691t-d26d1d788d94b23e217ef951ff89fc04105801111add5e8ca3acba5dd3a4acd73</citedby><cites>FETCH-LOGICAL-c691t-d26d1d788d94b23e217ef951ff89fc04105801111add5e8ca3acba5dd3a4acd73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280251/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280251/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22355332$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Chai, Karl X.</contributor><creatorcontrib>Rehman, Ishtiaq</creatorcontrib><creatorcontrib>Evans, Caroline A</creatorcontrib><creatorcontrib>Glen, Adam</creatorcontrib><creatorcontrib>Cross, Simon S</creatorcontrib><creatorcontrib>Eaton, Colby L</creatorcontrib><creatorcontrib>Down, Jenny</creatorcontrib><creatorcontrib>Pesce, Giancarlo</creatorcontrib><creatorcontrib>Phillips, Joshua T</creatorcontrib><creatorcontrib>Yen, Ow Saw</creatorcontrib><creatorcontrib>Thalmann, George N</creatorcontrib><creatorcontrib>Wright, Phillip C</creatorcontrib><creatorcontrib>Hamdy, Freddie C</creatorcontrib><title>iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>A major challenge in the management of patients with prostate cancer is identifying those individuals at risk of developing metastatic disease, as in most cases the disease will remain indolent. We analyzed pooled serum samples from 4 groups of patients (n = 5 samples/group), collected prospectively and actively monitored for a minimum of 5 yrs. Patients groups were (i) histological diagnosis of benign prostatic hyperplasia with no evidence of cancer 'BPH', (ii) localised cancer with no evidence of progression, 'non-progressing' (iii) localised cancer with evidence of biochemical progression, 'progressing', and (iv) bone metastasis at presentation 'metastatic'. Pooled samples were immuno-depleted of the 14 most highly abundant proteins and analysed using a 4-plex iTRAQ approach. Overall 122 proteins were identified and relatively quantified. Comparisons of progressing versus non-progressing groups identified the significant differential expression of 25 proteins (p<0.001). Comparisons of metastatic versus progressing groups identified the significant differential expression of 23 proteins. Mapping the differentially expressed proteins onto the prostate cancer progression pathway revealed the dysregulated expression of individual proteins, pairs of proteins and 'panels' of proteins to be associated with particular stages of disease development and progression. The median immunostaining intensity of eukaryotic translation elongation factor 1 alpha 1 (eEF1A1), one of the candidates identified, was significantly higher in osteoblasts in close proximity to metastatic tumour cells compared with osteoblasts in control bone (p = 0.0353, Mann Whitney U). Our proteomic approach has identified leads for potentially useful serum biomarkers associated with the metastatic progression of prostate cancer. The panels identified, including eEF1A1 warrant further investigation and validation.</description><subject>Aged</subject><subject>Androgens</subject><subject>Antigens</subject><subject>Biocompatibility</subject><subject>Bioengineering</subject><subject>Biological markers</subject><subject>Biology</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biomarkers, Tumor - metabolism</subject><subject>Biomedical materials</subject><subject>Blotting, Western</subject><subject>Bone cancer</subject><subject>Bone Neoplasms - genetics</subject><subject>Bone Neoplasms - metabolism</subject><subject>Bone Neoplasms - secondary</subject><subject>Bones</subject><subject>Cancer</subject><subject>Cancer metastasis</subject><subject>Cloning</subject><subject>Cytokines</subject><subject>Developmental stages</subject><subject>Diagnosis</subject><subject>Disease</subject><subject>Disease Progression</subject><subject>Elongation</subject><subject>Health risks</subject><subject>Humans</subject><subject>Hyperplasia</subject><subject>Identification</subject><subject>Immunoenzyme Techniques</subject><subject>Male</subject><subject>Mass spectrometry</subject><subject>Medical diagnosis</subject><subject>Medical prognosis</subject><subject>Medical schools</subject><subject>Medicine</subject><subject>Metabolism</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Neoplasm Grading</subject><subject>Osteoblasts</subject><subject>Osteosarcoma - genetics</subject><subject>Osteosarcoma - metabolism</subject><subject>Osteosarcoma - secondary</subject><subject>Panels</subject><subject>Patients</subject><subject>Peptide Elongation Factor 1 - genetics</subject><subject>Peptide Elongation Factor 1 - metabolism</subject><subject>Peptide mapping</subject><subject>Prospective Studies</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Hyperplasia - genetics</subject><subject>Prostatic Hyperplasia - metabolism</subject><subject>Prostatic Hyperplasia - pathology</subject><subject>Prostatic Neoplasms - genetics</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Proteins</subject><subject>Proteomics</subject><subject>Real-Time Polymerase Chain Reaction</subject><subject>RNA, Messenger - genetics</subject><subject>Scientific imaging</subject><subject>Tandem Mass Spectrometry</subject><subject>Translation elongation</subject><subject>Tumor Cells, Cultured</subject><subject>Tumors</subject><subject>Urology</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk9tu1DAQhiMEoqXwBggiIYG42MWHHOwbpFXFYaVKFaVwa008zq6XJF7shMPb47BptUG9ILlINPP9vzOTmSR5SsmS8pK-2bnBd9As964zS0I4ESK_l5xSydmiYITfP3o_SR6FsCMk56IoHiYnjPE855ydJt5eX60-pRZN19vaauit61JXpxo6tAi9SYPxQ5tW1rXgvxkfUgjBaRtTmP60_TZtTQ-hj0qd7r3beBPCZLIdWujG4Jg2o6c2_nHyoIYmmCfT8yz58v7d9fnHxcXlh_X56mKhC0n7BbICKZZCoMwqxg2jpallTutayFqTjJJcEBovQMyN0MBBV5AjcshAY8nPkucH333jgpraFRSNdctMEjkS6wOBDnZq722s8LdyYNXfgPMbBT6W1RhVQqZLJBkgw0wwLYq81BUiVBwkJxi93k6nDVVrUMd-emhmpvNMZ7dq434ozgRhOY0GryYD774PJvSqtUGbpoHOuCEoyTiVRDAeyRf_kHcXN1EbiN9vu9rFY_XoqVZZWRLBeZFFankHFW80rdVxtGob4zPB65kgMr351W9gCEGtP1_9P3v5dc6-PGK3Bpp-G1wzjPMY5mB2AHUcq-BNfdtjStS4GTfdUONmqGkzouzZ8f-5Fd2sAv8DNaQLhw</recordid><startdate>20120215</startdate><enddate>20120215</enddate><creator>Rehman, Ishtiaq</creator><creator>Evans, Caroline A</creator><creator>Glen, Adam</creator><creator>Cross, Simon S</creator><creator>Eaton, Colby L</creator><creator>Down, Jenny</creator><creator>Pesce, Giancarlo</creator><creator>Phillips, Joshua T</creator><creator>Yen, Ow Saw</creator><creator>Thalmann, George N</creator><creator>Wright, Phillip C</creator><creator>Hamdy, Freddie C</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20120215</creationdate><title>iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer</title><author>Rehman, Ishtiaq ; Evans, Caroline A ; Glen, Adam ; Cross, Simon S ; Eaton, Colby L ; Down, Jenny ; Pesce, Giancarlo ; Phillips, Joshua T ; Yen, Ow Saw ; Thalmann, George N ; Wright, Phillip C ; Hamdy, Freddie C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c691t-d26d1d788d94b23e217ef951ff89fc04105801111add5e8ca3acba5dd3a4acd73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Androgens</topic><topic>Antigens</topic><topic>Biocompatibility</topic><topic>Bioengineering</topic><topic>Biological markers</topic><topic>Biology</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biomarkers, Tumor - metabolism</topic><topic>Biomedical materials</topic><topic>Blotting, Western</topic><topic>Bone cancer</topic><topic>Bone Neoplasms - genetics</topic><topic>Bone Neoplasms - metabolism</topic><topic>Bone Neoplasms - secondary</topic><topic>Bones</topic><topic>Cancer</topic><topic>Cancer metastasis</topic><topic>Cloning</topic><topic>Cytokines</topic><topic>Developmental stages</topic><topic>Diagnosis</topic><topic>Disease</topic><topic>Disease Progression</topic><topic>Elongation</topic><topic>Health risks</topic><topic>Humans</topic><topic>Hyperplasia</topic><topic>Identification</topic><topic>Immunoenzyme Techniques</topic><topic>Male</topic><topic>Mass spectrometry</topic><topic>Medical diagnosis</topic><topic>Medical prognosis</topic><topic>Medical schools</topic><topic>Medicine</topic><topic>Metabolism</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Neoplasm Grading</topic><topic>Osteoblasts</topic><topic>Osteosarcoma - genetics</topic><topic>Osteosarcoma - metabolism</topic><topic>Osteosarcoma - secondary</topic><topic>Panels</topic><topic>Patients</topic><topic>Peptide Elongation Factor 1 - genetics</topic><topic>Peptide Elongation Factor 1 - metabolism</topic><topic>Peptide mapping</topic><topic>Prospective Studies</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Hyperplasia - genetics</topic><topic>Prostatic Hyperplasia - metabolism</topic><topic>Prostatic Hyperplasia - pathology</topic><topic>Prostatic Neoplasms - genetics</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Proteins</topic><topic>Proteomics</topic><topic>Real-Time Polymerase Chain Reaction</topic><topic>RNA, Messenger - genetics</topic><topic>Scientific imaging</topic><topic>Tandem Mass Spectrometry</topic><topic>Translation elongation</topic><topic>Tumor Cells, Cultured</topic><topic>Tumors</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rehman, Ishtiaq</creatorcontrib><creatorcontrib>Evans, Caroline A</creatorcontrib><creatorcontrib>Glen, Adam</creatorcontrib><creatorcontrib>Cross, Simon S</creatorcontrib><creatorcontrib>Eaton, Colby L</creatorcontrib><creatorcontrib>Down, Jenny</creatorcontrib><creatorcontrib>Pesce, Giancarlo</creatorcontrib><creatorcontrib>Phillips, Joshua T</creatorcontrib><creatorcontrib>Yen, Ow Saw</creatorcontrib><creatorcontrib>Thalmann, George N</creatorcontrib><creatorcontrib>Wright, Phillip C</creatorcontrib><creatorcontrib>Hamdy, Freddie C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rehman, Ishtiaq</au><au>Evans, Caroline A</au><au>Glen, Adam</au><au>Cross, Simon S</au><au>Eaton, Colby L</au><au>Down, Jenny</au><au>Pesce, Giancarlo</au><au>Phillips, Joshua T</au><au>Yen, Ow Saw</au><au>Thalmann, George N</au><au>Wright, Phillip C</au><au>Hamdy, Freddie C</au><au>Chai, Karl X.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2012-02-15</date><risdate>2012</risdate><volume>7</volume><issue>2</issue><spage>e30885</spage><epage>e30885</epage><pages>e30885-e30885</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>A major challenge in the management of patients with prostate cancer is identifying those individuals at risk of developing metastatic disease, as in most cases the disease will remain indolent. We analyzed pooled serum samples from 4 groups of patients (n = 5 samples/group), collected prospectively and actively monitored for a minimum of 5 yrs. Patients groups were (i) histological diagnosis of benign prostatic hyperplasia with no evidence of cancer 'BPH', (ii) localised cancer with no evidence of progression, 'non-progressing' (iii) localised cancer with evidence of biochemical progression, 'progressing', and (iv) bone metastasis at presentation 'metastatic'. Pooled samples were immuno-depleted of the 14 most highly abundant proteins and analysed using a 4-plex iTRAQ approach. Overall 122 proteins were identified and relatively quantified. Comparisons of progressing versus non-progressing groups identified the significant differential expression of 25 proteins (p<0.001). Comparisons of metastatic versus progressing groups identified the significant differential expression of 23 proteins. Mapping the differentially expressed proteins onto the prostate cancer progression pathway revealed the dysregulated expression of individual proteins, pairs of proteins and 'panels' of proteins to be associated with particular stages of disease development and progression. The median immunostaining intensity of eukaryotic translation elongation factor 1 alpha 1 (eEF1A1), one of the candidates identified, was significantly higher in osteoblasts in close proximity to metastatic tumour cells compared with osteoblasts in control bone (p = 0.0353, Mann Whitney U). Our proteomic approach has identified leads for potentially useful serum biomarkers associated with the metastatic progression of prostate cancer. The panels identified, including eEF1A1 warrant further investigation and validation.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>22355332</pmid><doi>10.1371/journal.pone.0030885</doi><tpages>e30885</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2012-02, Vol.7 (2), p.e30885-e30885 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1332949097 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Public Library of Science (PLoS) Journals Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry |
| subjects | Aged Androgens Antigens Biocompatibility Bioengineering Biological markers Biology Biomarkers Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Biomedical materials Blotting, Western Bone cancer Bone Neoplasms - genetics Bone Neoplasms - metabolism Bone Neoplasms - secondary Bones Cancer Cancer metastasis Cloning Cytokines Developmental stages Diagnosis Disease Disease Progression Elongation Health risks Humans Hyperplasia Identification Immunoenzyme Techniques Male Mass spectrometry Medical diagnosis Medical prognosis Medical schools Medicine Metabolism Metastases Metastasis Neoplasm Grading Osteoblasts Osteosarcoma - genetics Osteosarcoma - metabolism Osteosarcoma - secondary Panels Patients Peptide Elongation Factor 1 - genetics Peptide Elongation Factor 1 - metabolism Peptide mapping Prospective Studies Prostate cancer Prostate-Specific Antigen - blood Prostatic Hyperplasia - genetics Prostatic Hyperplasia - metabolism Prostatic Hyperplasia - pathology Prostatic Neoplasms - genetics Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology Proteins Proteomics Real-Time Polymerase Chain Reaction RNA, Messenger - genetics Scientific imaging Tandem Mass Spectrometry Translation elongation Tumor Cells, Cultured Tumors Urology |
| title | iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T06%3A22%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=iTRAQ%20identification%20of%20candidate%20serum%20biomarkers%20associated%20with%20metastatic%20progression%20of%20human%20prostate%20cancer&rft.jtitle=PloS%20one&rft.au=Rehman,%20Ishtiaq&rft.date=2012-02-15&rft.volume=7&rft.issue=2&rft.spage=e30885&rft.epage=e30885&rft.pages=e30885-e30885&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0030885&rft_dat=%3Cgale_plos_%3EA477083364%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1332949097&rft_id=info:pmid/22355332&rft_galeid=A477083364&rft_doaj_id=oai_doaj_org_article_7a4c7d04ad2d482c8657cbddab3a930d&rfr_iscdi=true |